Can fish oil and a brain booster slow dementia?

NCT ID NCT05181189

Not yet recruiting Disease control Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a drug called DAOIB, which boosts brain signaling, combined with omega-3 fatty acids can improve thinking and daily life in people with early Alzheimer's or mild cognitive impairment. 140 participants will receive either the combo or a placebo for 24 weeks. Researchers will check memory and function every 8 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DAOIB (a drug that enhances NMDA receptor function) combined with omega-3 fatty acids
What this could lead to: If successful, this combination could offer a new way to slow cognitive decline in early dementia, improving memory and daily function.
What could go wrong: This is an early Phase 2 trial with only 140 people, so results may not apply broadly. The treatment may not outperform placebo, and omega-3 doses are adjusted individually, which could affect consistency.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEMENTIA OMEGA-3 FATTY ACIDS

Contacts and locations

Locations

Kaohsiung Chang Gung Memorial Hospital

Kaohsiung City, 886, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.